Core Insights - Aclarion, Inc. has published a CEO Shareholder Letter outlining strategic progress and upcoming catalysts for 2026, emphasizing the company's focus on expanding the adoption of its Nociscan platform and enhancing clinical evidence and reimbursement initiatives [2][3][4] Financial Performance - For the three months ended May 31, 2024, Aclarion reported total revenue of $5,031,000, a 40% increase from $3,603,000 in the same period of 2023 [1] - Revenue breakdown includes: - Fluxing Systems: $134,000 (2% of total), down 43% from $236,000 (6% of total) in 2023 - Integrated Coating Systems: $747,000 (15% of total), up 142% from $309,000 (9% of total) in 2023 - Multi-Axis Coating Systems: $2,664,000 (53% of total), up 51% from $1,763,000 (49% of total) in 2023 - OEM Systems: $332,000 (7% of total), up 21% from $274,000 (8% of total) in 2023 - Spare Parts, Services, and Other: $1,154,000 (23% of total), up 13% from $1,021,000 (28% of total) in 2023 [1] Strategic Initiatives - The company is pursuing reimbursement coverage from regional insurance providers in the U.S. as a critical step towards broader payer adoption [2] - Aclarion is advancing its ongoing CLARITY clinical trial, with initial readout expected in Q4 2026, and is expanding commercial engagement with physicians and imaging centers [3][4] - The company maintains a strong balance sheet with a cash runway extending into 2028, supporting its strategic initiatives [2][3]

Core Insights - Aclarion, Inc. is participating in the 38th Annual ROTH Conference from March 22-24, 2026, to discuss its proprietary MR spectroscopy platform, Nociscan, aimed at identifying chronic low back pain [1][2] Company Overview - Aclarion is a commercial-stage healthcare technology company utilizing biomarkers and augmented intelligence algorithms to assist physicians in diagnosing chronic low back pain [1][4] - The company’s Nociscan platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [4] Financial Position - Aclarion has a strong balance sheet with no debt, positioning the company well for future growth and expansion of Nociscan in both the UK and US markets [3] Conference Engagement - CEO Brent Ness will hold one-on-one meetings with institutional investors and analysts during the ROTH Conference to discuss the company's advancements and future catalysts [2][3]

Financial Data and Key Metrics Changes - In Q4 2025, revenues grew 17% and EBITDA grew 29% year-over-year in US dollars [4] - For the full year, revenues increased nearly 10% and EBITDA grew 19% [4] - Annual EBITDA surpassed $2 billion with margins expanding to 45.7% [4][8] - Group revenue reached $4.4 billion in 2025, growing 9.9% in US dollar terms [16] - EBITDA for the year reached $2.01 billion, representing 18.8% growth [16] Business Line Data and Key Metrics Changes - Digital services revenue grew 84% year-over-year in Q4 and over 62% for the full year [4] - Digital revenues reached $759 million, representing 17% of group revenues for the full year [9][16] - EBITDA from digital services reached $207 million with an EBITDA margin of 27.3% [5] - Telecom and infrastructure revenues grew 3% despite the consolidation of TNS Plus, Deodar, and Kyrgyzstan [8] Market Data and Key Metrics Changes - Growth across markets remains balanced, with strong momentum in Pakistan, Ukraine, and Kazakhstan [10] - Bangladesh returned to positive growth during the year, while Uzbekistan continues to expand steadily [10] - Monthly active users in Pakistan's financial services business reached 21.5 million, with transaction value reaching $53 billion [11] Company Strategy and Development Direction - The company is focused on executing an asset-light strategy, having completed the sale of its Pakistan tower portfolio [5] - The listing of Kyivstar on Nasdaq was highlighted as a significant achievement [7] - The company aims to continue annual share buybacks of at least $100 million, reflecting confidence in long-term cash generation capacity [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in both telecommunications and digital services [18] - The company expects revenue growth of 9%-12% and EBITDA growth of 7%-10% for 2026 [18] - Management acknowledged the impact of inflation and pricing power in their markets [104] Other Important Information - The company is actively pursuing digital banking licenses across its markets, including Pakistan [88] - The acquisition of TPL Insurance is expected to enhance embedded insurance offerings through JazzCash [84] - The company is developing local language large models for AI applications in its markets [95] Q&A Session Summary Question: Inquiry about the Pakistan spectrum auction and 5G network aspirations - Management highlighted the successful spectrum auction in Pakistan and the potential for both 4G and 5G network improvements [24][25] Question: Revenue growth drivers and pricing versus volume - Management attributed revenue growth to a shift towards meaningful digital services and multi-play customer relationships [32][33] Question: Future digital revenue growth and margin profile - Management indicated a balanced model for cash flow generation between telecom and digital services, with a current digital margin of 27.3% [35] Question: Capital allocation and mid-term strategy - Management emphasized a disciplined approach to capital allocation, focusing on share buybacks and strategic acquisitions [46][50] Question: Ukraine market potential and future projections - Management expressed confidence in Ukraine's long-term growth potential post-conflict, highlighting digital service opportunities [62][63] Question: Settlement with Dhabi Group and implications - Management explained the rationale behind settling with Dhabi Group to eliminate distractions and enhance investor relations [67][76] Question: Embedded insurance strategy and digital banking licenses - Management discussed the integration of insurance products into existing platforms and the pursuit of digital banking licenses [84][88]

Core Insights - Aclarion, Inc. is participating in LSI USA 2026 to discuss advancements in its proprietary MR spectroscopy platform, NOCISCAN, aimed at addressing chronic low back pain [1][2]. Company Overview - Aclarion is a commercial-stage healthcare technology company utilizing biomarkers and augmented intelligence algorithms to assist physicians in identifying chronic low back pain [1]. - The company’s NOCISCAN platform is the first evidence-supported SaaS solution designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3]. Product Details - NOCISCAN employs Magnetic Resonance Spectroscopy (MRS) to analyze data from MRI machines, extracting chemical biomarkers associated with disc pain [3]. - The platform integrates proprietary signal processing techniques and algorithms to provide insights into the source of a patient's low back pain, aiding in treatment optimization [3]. Event Participation - Brent Ness, CEO of Aclarion, will attend LSI USA 2026 from March 16-20, 2026, in Dana Point, CA, to engage with investors and industry partners [2][3]. - The event focuses on accelerating innovation in MedTech and HealthTech, bringing together key stakeholders in the industry [3].

Core Insights - Aclarion, Inc. is advancing towards an expected initial internal readout of its 300-patient CLARITY trial by the end of Q3 2026, with public disclosure of early interim results anticipated in Q4 2026 [1][2] Financial Position - The company has a strengthened balance sheet with a cash runway extending into 2028, allowing it to complete the CLARITY trial without the need for additional capital raises [2][7] - Aclarion has terminated its ATM and its ELOC expired at the end of 2025, reinforcing its commitment to shareholder alignment [2] Business Model and Technology - Aclarion operates as a software-native MedTech innovator, delivering solutions entirely through the cloud, which allows for software-level gross margins and rapid scalability [3] - The company's Nociscan platform utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to help physicians identify the source of chronic low back pain noninvasively [5] Strategic Initiatives - In 2026, Aclarion will implement a structured investor-awareness strategy targeting institutional healthcare investors and enhancing visibility in financial and medical media [4]

Core Insights - VSee Health, Inc. has announced a strategic partnership with DocBox to develop a next-generation Virtual ICU operating system for hospitals globally [1] Company Overview - VSee Health, Inc. is recognized as a leader in enterprise telehealth and AI-powered virtual care [1] - DocBox is identified as the first Augmented Intelligence platform specifically designed for critical care [1] Industry Implications - The collaboration aims to create a scalable, AI-native Virtual ICU platform that is expected to drive new recurring revenue and enhance enterprise value for healthcare providers [1]

Core Insights - Aclarion has successfully strengthened its balance sheet and extended its cash runway into 2028 through a $10.4 million financing, enhancing its operational flexibility and supporting its commercialization efforts for Nociscan [2][3][5] Financial Performance - For the three months ended May 31, 2024, Aclarion reported total revenues of $5.031 million, a 40% increase from $3.603 million in the same period of 2023 [1] - The revenue breakdown includes: - Fluxing Systems: $134,000 (2% of total), down 43% from $236,000 (6% of total) - Integrated Coating Systems: $747,000 (15% of total), up 142% from $309,000 (9% of total) - Multi-Axis Coating Systems: $2.664 million (53% of total), up 51% from $1.763 million (49% of total) - OEM Systems: $332,000 (7% of total), up 21% from $274,000 (8% of total) - Spare Parts, Services, and Other: $1.154 million (23% of total), up 13% from $1.021 million (28% of total) [1] Capital Structure - Aclarion's balance sheet is now debt-free with $21.6 million in cash as of January 12, 2026, allowing for a significant extension of its cash runway [6] - The financing has preserved the integrity of the capital structure and supports ongoing commercialization and strategic partnerships [3][4] Strategic Focus - The company aims to enhance the adoption of Nociscan, deepen clinical evidence, and build strategic relationships to drive growth for patients, providers, payers, and shareholders [5] - Upcoming milestones include accelerating enrollment in the CLARITY trial, expanding access to major MRI manufacturers, and collaborating with commercial payers for reimbursement coverage of Nociscan [11]

Core Insights - Aclarion, Inc. has successfully closed a $10.4 million financing round at $5.18 per share, resulting in a debt-free balance sheet and $21.6 million in cash as of January 12, 2026 [1][7] - The financing enhances Aclarion's capital structure, extends its operational runway into 2028, and supports ongoing commercialization and strategic partnerships for its Nociscan technology [2][4] Financial Highlights - The company has transformed its balance sheet over the past year, positioning itself for long-term value creation with a strong capital structure [3] - Aclarion's cash reserves and extended cash runway allow for focused execution on key objectives, including expanding adoption of Nociscan and deepening clinical evidence [4][7] Upcoming Milestones and Objectives - Aclarion aims to accelerate enrollment in the CLARITY trial, targeting approximately 25% of patients by the end of Q2 2026, with initial readouts expected after the first cohort's follow-up [8] - The company plans to complete and publish multiple real-world evidence trials and expand access to major MRI manufacturers, increasing the global market size by over 30% [8] - Aclarion will support clinician education through participation in CME events and refine workflow integration with the launch of Nociscan software version 2.8 in Q1 [8] - Collaboration with commercial payers in the US market is ongoing to evaluate broad reimbursement coverage for Nociscan [8]

Core Insights - Aclarion, Inc. is advancing its proprietary Nociscan platform to transform the diagnosis of chronic low back pain, reporting significant growth in scan volumes and a strong financial position as it enters 2026 [1][5][9] Market Adoption & Growth Momentum - In 2025, Aclarion achieved a 69% year-over-year increase in annual Nociscan scan volumes, with Q4 2025 scan volumes growing by 114% year-over-year [2][5][6] Strategic and Operational Highlights - The company added 9 new imaging centers and 22 new physician users in 2025, expanding its commercial presence in key UK and U.S. healthcare markets [6] - Aclarion is focused on enrolling approximately 25% of patients in the CLARITY trial by the end of Q2 2026, with the first internal readout of interim data expected in Q3 2026 [5][6] Clinical and Product Developments - The Nociscan platform has shown to be more effective and less costly than traditional methods, saving $1,712 per patient and improving surgical success rates by 10% [6] - Aclarion published significant clinical evidence in 2025, including a cost-effectiveness analysis and a case study in the International Journal of Spine Surgery [6] Financial Highlights - As of December 31, 2025, Aclarion had $12.0 million in cash and no debt, having raised over $22.0 million in equity financing during fiscal 2025 [7][8] - The company believes its existing cash resources are sufficient to fund operations into the first half of 2027 [8] Management Commentary - The CEO of Aclarion expressed satisfaction with the company's progress in strengthening its financial position and expanding clinical traction, emphasizing the importance of evidence generation and strategic partnerships for long-term value [9][10] Future Plans - Aclarion aims to expand access to major MRI manufacturers, support clinician education initiatives, and refine workflow integration with the launch of version 2.8 of the Nociscan software in Q1 [12]

Core Insights - Aclarion, Inc. has initiated patient enrollment in its pivotal CLARITY trial, which aims to evaluate the effectiveness of its Nociscan technology for chronic low back pain [1][2] Group 1: Trial Progress and Enrollment - Northwestern Medicine and Scripps Health have enrolled their first patients, contributing to the overall progress of the CLARITY trial [1][2] - Four clinical sites have enrolled patients, with seven sites having completed necessary regulatory approvals and preparations for patient enrollment [2] - The company aims to enroll approximately 25% of the total 300 patients by the end of Q2 2026, with an initial readout of results expected 90 days after the last patient completes their 3-month follow-up [5][8] Group 2: Clinical Objectives and Methodology - The CLARITY trial is designed to assess whether the integration of Nociscan into surgical planning can improve patient outcomes beyond the current industry benchmark of approximately 54% for chronic low back pain surgeries [4] - The trial will randomize patients between those who are blinded and unblinded to Nociscan results, focusing on surgical planning for Fusion/TDR procedures [4] Group 3: Company Strategy and Leadership - Aclarion has appointed Jason Brosniak as Commercial Director for the Eastern U.S. and Andy Murillo as Director of Market Access to enhance trial enrollment and site expansion [3] - The company views the CLARITY trial as a foundational initiative for value creation, aiming to generate high-quality clinical evidence and support long-term shareholder value [6] Group 4: Market Context and Technology - Chronic low back pain affects an estimated 266 million people globally, highlighting the significance of Aclarion's Nociscan solution, which is the first evidence-supported SaaS platform to help differentiate between painful and nonpainful discs [7] - Nociscan utilizes Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms to quantify biomarkers associated with disc pain, potentially improving surgical outcomes for patients with degenerative spine disease [9]